USPTO serial 98035470
TAKEDA
Reviewed by CopyMark Law Group
Status 732Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- GRYGIEL, JONATHAN C
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with TAKEDA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,246*
Plus Government fees of $600
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Karl M. Zielaznicki, Esq.
Karl M. Zielaznicki, Esq. Troutman Pepper Locke LLP875 THIRD AVENUEC/O IP SERVICES NYCNEW YORK, NY 10022Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable virtual goods, namely, computer programs featuring pharmaceutical preparations for treating or diagnosing disorders, diseases, and rare diseases, medical devices used for administering pharmaceutical preparations, medical devices for reconstituting pharmaceutical preparations, medical devices for reconstituting and administering pharmaceutical preparations, and pharmaceutical preparations and medical devices associated with health care and medical services, namely, pharmaceutical patient support program, healthcare provider support program, and medical professional support program providing health and medical information in the field of pharmaceutical products and services, with all of the aforementioned goods in the field of autoimmunology, bacterial infection diseases and disorders, cardiology, central and peripheral nervous systems diseases and disorders, diabetes, endocrinology, hematology, hormonal diseases and disorders, gastroenterology, gout, immunology, infectious diseases and disorders, inflammatory diseases and disorders, musculoskeletal diseases and disorders, neuroscience, oncology, pain management, respiratory diseases and disorders, genetic diseases and disorders, urological diseases and disorders, kidney diseases and disorders, viral diseases and disorders, for use in online virtual environments, augmented reality, extended reality, and mixed reality environments; Downloadable digital image files of pharmaceutical preparations for treating or diagnosing disorders, diseases, and rare diseases, medical devices used for administering pharmaceutical preparations, medical devices for reconstituting pharmaceutical preparations, medical devices for reconstituting and administering pharmaceutical preparations, and pharmaceutical preparations and medical devices associated with health care and medical services, namely, pharmaceutical patient support program, healthcare provider support program, and medical professional support program providing health and medical information in the field of pharmaceutical products and services, with all of the aforementioned goods in the field of autoimmunology, bacterial infection diseases and disorders, cardiology, central and peripheral nervous systems diseases and disorders, diabetes, endocrinology, hematology, hormonal diseases and disorders, gastroenterology, gout, immunology, infectious diseases and disorders, inflammatory diseases and disorders, musculoskeletal diseases and disorders, neuroscience, oncology, pain management, respiratory diseases and disorders, genetic diseases and disorders, urological diseases and disorders, kidney diseases and disorders, viral diseases and disorders authenticated by non-fungible tokens (NFTs); Downloadable computer software for providing access to online virtual environments, augmented reality, extended reality, and mixed reality environments related to pharmaceutical preparations, medical devices, health care and medical services; Downloadable computer software for providing access to online virtual environments, augmented reality, extended reality, and mixed reality environments related to educational services in the field of pharmaceuticals, medicines, health care and medical services; Downloadable computer software for providing access to games in online virtual environments, augmented reality, extended reality, and mixed reality environments; Downloadable computer software for providing access to video games | ACTIVE | — |
| 035 | Providing online retail store services featuring virtual or mixed reality software that displays virtual goods and enables customers to purchase and store virtual goods and services related to pharmaceutical preparations, medical devices, health care and medical services for use in online virtual environments, augmented reality, extended reality, and mixed reality; Providing online marketplace services featuring virtual or mixed reality software that displays virtual goods and enables customers to purchase and store virtual goods and services for buyers and sellers of virtual goods related to pharmaceutical preparations, medical devices, health care and medical services for use in online virtual environments, augmented reality, extended reality, and mixed reality environments | ACTIVE | — |
| 041 | Entertainment services, namely, providing online, non-downloadable virtual goods, in particular, pharmaceutical preparations for treating or diagnosing disorders, diseases, and rare diseases, medical devices used for administering pharmaceutical preparations, medical devices for reconstituting pharmaceutical preparations, medical devices for reconstituting and administering pharmaceutical preparations, and pharmaceutical preparations and medical devices associated with health care and medical services, namely, pharmaceutical patient support program, healthcare provider support program, and medical professional support program providing health and medical information in the field of pharmaceutical products and services, with all of the aforementioned goods in the field of autoimmunology, bacterial infection diseases and disorders, cardiology, central and peripheral nervous systems diseases and disorders, diabetes, endocrinology, hematology, hormonal diseases and disorders, gastroenterology, gout, immunology, infectious diseases and disorders, inflammatory diseases and disorders, musculoskeletal diseases and disorders, neuroscience, oncology, pain management, respiratory diseases and disorders, genetic diseases and disorders, urological diseases and disorders, kidney diseases and disorders, viral diseases and disorders for use in online virtual environments, augmented reality, extended reality, and mixed reality environments created for entertainment purposes; Entertainment services, namely, providing online, non-downloadable virtual environments, augmented reality, extended reality, and mixed reality environment video games in which users can interact for recreational, leisure, or entertainment purposes; Entertainment services, namely, providing online, non-downloadable video games; Entertainment services, namely, providing online virtual environments, augmented reality, extended reality, and mixed reality environments in which users can interact for recreational purposes | ACTIVE | — |
| 042 | Providing temporary use of non-downloadable computer software for the purchase and transfer of digital media, namely, digital assets, digital collectibles, digital tokens and non-fungible tokens (NFTs) for virtual goods related to pharmaceutical preparations for treating or diagnosing disorders, diseases, and rare diseases, medical devices used for administering pharmaceutical preparations, medical devices for reconstituting pharmaceutical preparations, medical devices for reconstituting and administering pharmaceutical preparations, and pharmaceutical preparations and medical devices associated with health care and medical services, namely, pharmaceutical patient support program, healthcare provider support program, and medical professional support program providing health and medical information in the field of pharmaceutical products and services, with all of the aforementioned goods in the field of autoimmunology, bacterial infection diseases and disorders, cardiology, central and peripheral nervous systems diseases and disorders, diabetes, endocrinology, hematology, hormonal diseases and disorders, gastroenterology, gout, immunology, infectious diseases and disorders, inflammatory diseases and disorders, musculoskeletal diseases and disorders, neuroscience, oncology, pain management, respiratory diseases and disorders, genetic diseases and disorders, urological diseases and disorders, kidney diseases and disorders, viral diseases and disorders for use in online virtual environments, augmented reality, extended reality, and mixed reality environments; Providing temporary use of non-downloadable computer software for providing access to online virtual environments, augmented reality, extended reality, and mixed reality environments related to pharmaceutical preparations, medical devices, health care and medical services; Providing temporary use of non-downloadable computer software for providing access to online virtual environments, augmented reality, extended reality, and mixed reality environments related to educational services in the field of medicines, pharmaceuticals, health care and medical services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Takeda Pharmaceutical Company Limited
- Other trademarks owned by Takeda Pharmaceutical Company Limited
- Other trademarks in Class 009
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named TAKEDA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 15, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 14, 2026 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Oct 14, 2026 | EXT3 | SOU EXTENSION 3 FILED | — |
| Oct 14, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 11, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 10, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 10, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Apr 10, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 14, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 13, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 13, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Nov 13, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 1, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 6, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 6, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 30, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 8, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 8, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 8, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 8, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 8, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 28, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 28, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jan 28, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 28, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 27, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jan 27, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 27, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 4, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 4, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 4, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 9, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 9, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 9, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 16, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 16, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 16, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 4, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 4, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 4, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 29, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 13, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 13, 2023 | NWAP | NEW APPLICATION ENTERED | — |